Bobadilla 1994.

Methods	Randomised clinical trial.
Participants	Country: Mexico. Number randomised: 40. Post‐randomisation dropouts: not stated. Revised sample size: 40. Mean age: not stated. Females: not stated. Symptomatic participants: not stated. AMA positive: not stated. Responders: not stated. Mean follow‐up period (for all groups): all participants followed up for 12 months. Inclusion criteria Symptom status: not stated. AMA status: not stated. Response status: not stated.
Interventions	Participants were randomly assigned to 2 groups. Group 1: UDCA (moderate) + colchicine (n = 21). Further details: UDCA: 13 mg/kg/day to 15 mg/kg/day for 1 year + colchicine: 1 mg/day for 5 days in a week for 1 year. Group 2: placebo (n = 19).
Outcomes	None of the outcomes of interest reported.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: information not available.
Allocation concealment (selection bias)	Unclear risk	Comment: information not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: although placebo used in double‐blind trial, unclear whether the placebo was identical.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: although placebo used in double‐blind trial, unclear whether the placebo was identical.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: information not available.
Selective reporting (reporting bias)	High risk	Comment: neither mortality nor adverse events reported.
For‐profit bias	Unclear risk	Comment: information not available.
Other bias	Low risk	Comment: no other source of bias.